Does targeting the lipophilic milieu provide advantages for an endothelin antagonist? - Wikidata - wikimedia - TriplyDB

Does targeting the lipophilic milieu provide advantages for an endothelin antagonist?

Does targeting the lipophilic milieu provide advantages for an endothelin antagonist?

http://www.wikidata.org/entity/Q42944137

about

The potential for macitentan, a new dual endothelin receptor antagonist, in the treatment of pulmonary arterial hypertension.

P2860

Q44607924-851CF19F-5BD7-4E44-B19F-899A9D4A7BA2

P2860

Does targeting the lipophilic milieu provide advantages for an endothelin antagonist?

http://www.wikidata.org/entity/Q42944137

description

2009 nî lūn-bûn

@nan

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

2009年论文

@zh

2009年论文

@zh-cn

name

Does targeting the lipophilic milieu provide advantages for an endothelin antagonist?

@en

Does targeting the lipophilic milieu provide advantages for an endothelin antagonist?

@nl

type

label

Does targeting the lipophilic milieu provide advantages for an endothelin antagonist?

@en

Does targeting the lipophilic milieu provide advantages for an endothelin antagonist?

@nl

prefLabel

Does targeting the lipophilic milieu provide advantages for an endothelin antagonist?

@en

Does targeting the lipophilic milieu provide advantages for an endothelin antagonist?

@nl

P1433

Q42944137-E79CD7D2-C493-4A21-82BC-AAAE7CE89726

P1476

Q42944137-1E8C2D6F-156D-47AF-AFB7-97BDAEFA5E35

P2093

Q42944137-4563FD26-00BB-4DDD-81BB-5ED794C51FF7

Q42944137-7FACD6F6-D863-4E70-B6B1-541B99C793FD

P2860

Q42944137-0FF81809-70C2-41E6-9A3A-67D0E4029A5D

Q42944137-148BC935-8DCA-4D50-9725-FDDBEDD78DF0

Q42944137-175E7558-CD5E-4338-99DF-1EE758C8CEAC

Q42944137-1F88292F-50F2-4EFD-BD49-5D604F0270DA

Q42944137-218190A2-2719-41DE-8AE3-9795936DB45B

Q42944137-2CF68A2B-FF47-4584-8A65-4FC0D64B1D6E

Q42944137-3781E39A-629C-4ECB-92BD-8794EDB2B9F7

Q42944137-3F945166-969F-4B5F-8C71-3719D4D2981C

Q42944137-42111A8F-DA49-4988-BAF3-CB34715A8B3E

Q42944137-4D7E146F-4D58-462F-AFF2-8B775FC50C9E

P304

Q42944137-08D8A980-5728-4D3C-84A0-043059A3A7C3

P31

Q42944137-13B7E3DB-FE54-4994-B443-FCF858C5472C

P356

Q42944137-B45A40FE-7933-45CD-B884-E1A19FBA482B

P433

Q42944137-DB54B6CE-13CD-4222-8A1D-82BF96BF2BE6

P478

Q42944137-D04165E2-8DE5-4800-9D5E-D920E4F956C0

P50

Q42944137-F44580C5-C8EB-40A3-AF3D-D564D3452650

P577

Q42944137-0228D220-0AFE-4EBF-BC6E-9E2EC523C94C

P5875

Q42944137-206895EE-6F80-48CB-90B4-D3880D993688

P698

Q42944137-41277C95-3E59-4085-9B78-EDF2FF7117CE

P932

Q42944137-80E6E6D6-6126-44EB-BDB3-A3001E335543

P356

P1433

Molecular Interventions: pharmacological perspectives from biology, chemistry and genomics

P1476

Does targeting the lipophilic milieu provide advantages for an endothelin antagonist?

@en

P2093

David M Pollock

http://www.w3.org/2001/XMLSchema#string

Stephen M Black

http://www.w3.org/2001/XMLSchema#string

P2860

ECE-1: a membrane-bound metalloprotease that catalyzes the proteolytic activation of big endothelin-1

The human endothelin-B receptor gene. Structural organization and chromosomal assignment

Cloning of a cDNA encoding a non-isopeptide-selective subtype of the endothelin receptor

Effectiveness of a nonselective ET(A/B) and a selective ET(A) antagonist in rats with monocrotaline-induced pulmonary hypertension.

Contrasting actions of endothelin ET(A) and ET(B) receptors in cardiovascular disease.

Sitaxsentan therapy for pulmonary arterial hypertension.

Bosentan: a dual endothelin receptor antagonist.

Acute pro-inflammatory actions of endothelin-1 in the guinea-pig lung: involvement of ETA and ETB receptors

Profile of past and current clinical trials involving endothelin receptor antagonists: the novel "-sentan" class of drug.

Inhibition of endothelin receptors in the treatment of pulmonary arterial hypertension: does selectivity matter?

P304

75-78

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1124/MI.9.2.6

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

9

http://www.w3.org/2001/XMLSchema#string

P50

P577

2009-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

24376465

http://www.w3.org/2001/XMLSchema#string

P698

19401539

http://www.w3.org/2001/XMLSchema#string

P932

2800997

http://www.w3.org/2001/XMLSchema#string